Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Burns

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
Lipids|September 1, 1977
Modification of the fatty acid composition of L1210 murine leukemia cellsC P Burns, D G Luttenegger, S P Wei, et al.
Archives of Biochemistry and Biophysics|September 25, 1999
Nitric oxide inhibits iron-induced lipid peroxidation in HL-60 cellsE E Kelley, B A Wagner, G R Buettner, et al.
Lipids|June 1, 1988
Modification of the fatty acid composition of L1210 leukemia subcellular organellesC P Burns, J A North, C J Mossman, et al.
Cancer Research|July 14, 1998
Sensitivity of K562 and HL-60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen speciesB A Wagner, G R Buettner, L W Oberley, et al.
Biochimica Et Biophysica Acta|December 13, 1982
Mechanism of defective sterol synthesis in human leukocytesC P Burns, I R Welshman, T J Scallen, et al.
Cancer Letters|January 1, 1987
Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cellsR A Hromas, P A Andrews, M P Murphy, et al.
Cancer Treatment Reports|July 1, 1981
Effect of chemotherapy for the dysmyelopoietic syndromeJ O Armitage, F R Dick, S W Needleman, et al.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|September 1, 1988
Subcellular distribution of doxorubicin: comparison of fatty acid-modified and unmodified cellsC P Burns, J A North, E S Petersen, et al.
Cancer|March 15, 1989
High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study GroupH M Lazarus, W R Vogler, C P Burns, et al.
Cancer|September 15, 1981
Hypoplastic acute leukemiaS W Needleman, C P Burns, F R Dick, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Lipids|September 1, 1977
Modification of the fatty acid composition of L1210 murine leukemia cellsC P Burns, D G Luttenegger, S P Wei, et al.
Archives of Biochemistry and Biophysics|September 25, 1999
Nitric oxide inhibits iron-induced lipid peroxidation in HL-60 cellsE E Kelley, B A Wagner, G R Buettner, et al.
Lipids|June 1, 1988
Modification of the fatty acid composition of L1210 leukemia subcellular organellesC P Burns, J A North, C J Mossman, et al.
Cancer Research|July 14, 1998
Sensitivity of K562 and HL-60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen speciesB A Wagner, G R Buettner, L W Oberley, et al.
Biochimica Et Biophysica Acta|December 13, 1982
Mechanism of defective sterol synthesis in human leukocytesC P Burns, I R Welshman, T J Scallen, et al.
Cancer Letters|January 1, 1987
Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cellsR A Hromas, P A Andrews, M P Murphy, et al.
Cancer Treatment Reports|July 1, 1981
Effect of chemotherapy for the dysmyelopoietic syndromeJ O Armitage, F R Dick, S W Needleman, et al.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|September 1, 1988
Subcellular distribution of doxorubicin: comparison of fatty acid-modified and unmodified cellsC P Burns, J A North, E S Petersen, et al.
Cancer|March 15, 1989
High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study GroupH M Lazarus, W R Vogler, C P Burns, et al.
Cancer|September 15, 1981
Hypoplastic acute leukemiaS W Needleman, C P Burns, F R Dick, et al.
Pageof 12